Read Time: 3 mins

Váro-centric Diabetes Management

Copy Link
Published Online: Nov 17th 2017 US Endocrinology, 2017;13(2):53–4 DOI:
Authors: Sanjay Kalra
Quick Links:
Article Information

While efficacy and safety are proven for all modern glucose-lowering drugs, their tolerability may vary. This is especially true in terms of weight gain. This communication proposes a váro-centric model of diabetes care. This approach helps choose appropriate glucose-lowering therapy, based upon weight (body mass index). The váro-centric model suggests a weight-centric approach to selection of drugs. While respecting the tenets of patient-centred care and good clinical sense, it serves as a clinical and teaching tool for rational prescription in diabetes.


Body mass index, dipeptidyl peptidase 4 inhibitors (DPP4i), glucagon like peptide receptor agonists (GLP1RA), insulin, pioglitazone, sodium glucose cotransporter 2 inhibitors (SGLT2i), sulfonylureas

  • Varo—a person dealing with things sensibly and realistically in a way that is based on practical rather than theoretical considerations (Urban Dictionary).
  • Város—weight, burden, overweight (Greek).
  • Vero—merchandise, trade good (Esperanto).

The phrase “patient-centered” defines modern diabetes care, and rightfully so.1 In patient-centered diabetology, the patient’s specific needs and requirements are taken into consideration while planning therapy. This helps achieve glycemic targets in a safe and well-tolerated manner. Current guidelines try to match the framework set by accepted definitions of patient centered care, as well as the bio-psychosocial model of health.2,3

The American Diabetes Association/European Association for Study of Diabetes (ADA/EASD) provide a horizontal choice of second-line drugs, and third-line combinations, to be prescribed in case of metformin inadequacy.1 It is clear that pleiotropic benefits, rather than efficacy per se, inform the choice of treatment. This style leaves the selection of a particular drug class (or classes) to the treating physician. For the student, or inexperienced caregiver, such a guideline does not assist in deciding techniques, tactics, and troubleshooting while treating diabetes.

The American Association of Clinical Endocrinology/American College of Endocrinologists (AACE/ACE) try to simplify matters by proposing a vertical hierarchy of drug classes.4 Here, glucose-lowering drugs are listed in descending order of appropriateness, based upon safety and tolerability. The main criterion for ranking seems to be the effect on weight, as weight loss is clearly mentioned, along with achievement of euglycemia, as a targeted outcome in type 2 diabetes care. Such a rubric, however, ignores the needs of underweight, lean, and normal-weight persons with diabetes.

To assist in clinical decision-making, we have proposed the concept of metabolic triage,5 based upon the metabolic fulcrum. In this model, persons with type 2 diabetes are triaged into three categories: eubolic, extremely catabolic, and maladaptive anabolic. This classification is based upon phenotype, and is backed by insights from pathophysiology, biochemistry and endocrinology.6,7 A type 2 diabetes person in catabolism will have predominant insulin deficiency, with a low insulin/glucagon ratio, and AMP-activated protein kinase (AMPK) hyperactivity. A maladaptive anabolic individual, on the other hand, will be predominantly insulin resistant, have a high insulin/glucagon ratio, and require AMPK activation. These factors help in choosing appropriate glucose-lowering treatment,5 including injectable therapy.8

The metabolic fulcrum is a simple, yet effective, clinical aid, as well as a pedagogic tool. We strengthen this further by proposing a váro-centric model of diabetes care. In Greek, “város” means weight or heaviness.9 As per the Urban Dictionary, varo is “a person dealing with things sensibly and realistically in a way that is based on practical rather than theoretical considerations”.10 In Esperanto, “varo” implies ware, trade goods, or merchandise.11

The váro-centric model of diabetes care suggests practical usage of available therapeutic options, based upon the weight (or body mass index) of the person with type 2 diabetes (Table 1). Such a model takes the needs of the individual person with diabetes into consideration, while promoting use of “good clinical sense”,12 to choose the most appropriate drug. Table 1 provides an evidence-based rubric, based upon the weight modulating effects of various drugs, to help decide optimal glucose-lowering treatment.

The váro-centric framework supports the recommendations of ADA/EASD and reflects the patient-centred philosophy of diabetology. It also reinforces AACE/ACE recommendations, which focus on weight control as a key factor in glycemic management. At the same time, it promotes good clinical sense by providing physicians with a simple framework upon which to base initial therapeutic strategies. The váro-centric model also highlights the synergy between patient, physician and pharmaceutical preparation. This is an unexpected literary spin off, created from the meanings of varo or város in Greek, Urban Dictionary, and Esperanto, respectively.

The váro-centric model is not complete in itself: demographic factors such as age; comorbid conditions such as endocrine and medical disease; and complications including macro- and micro-vascular dysfunction, must be taken into consideration while planning treatment. Psychosocial issues such as attitudes and ability to self-manage diabetes must be factored in. Personal and social perceptions about weight gain are also important, and should not be ignored.

With an understanding of these limitations and shortcomings, the váro-centric approach should become a globally accepted mode of clinical care in diabetology.

Article Information:

Sanjay Kalra has nothing to declare in relation to this article. No funding was received in the publication of this article. This article is a short opinion piece and
has not been submitted to external peer reviewers.


Sanjay Kalra, Department of Endocrinology, Bharti Hospital, Karnal, India. E:


This article is published under the Creative Commons Attribution Noncommercial License, which permits any noncommercial use, distribution, adaptation, and reproduction provided the original author(s) and source are given appropriate credit.




  1. Inzucchi SE, Bergenstal RM, Buse JB, et al., Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes, Diabetes Care, 2015;38:140–9.
  2. Kalra S, Balhara YP, Das AK, The bio-psycho-social model and the American Diabetes Association European Association for the Study of Diabetes position statement on management of hyperglycemia, J Soc Health Diabetes, 2013;1:53.
  3. Kalra S, Bantwal G, John M, The ADA-EASD patient-centered guidelines for management of hyperglycemia: Are they patient-centered enough?, J Soc Health Diabetes, 2013;1:41.
  4. Garber AJ, Abrahamson MJ, Barzilay JI, et al., Consensus statement by the American association of clinical endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm–2017 executive summary, Endocrine Practice, 2017;23:207–38.
  5. Kalra S, Gupta Y, Choice of glucose-lowering therapy – A metabolic fulcrum-based approach, US Endocrinol, 2015;11:79–80.
  6. Kalra S, Gupta Y, Patil S, Sodium-glucose cotransporter-2 inhibition and the insulin: Glucagon ratio: Unexplored dimensions, Indian J Endocrinol Metab, 2015;19:426.
  7. Dutta D, Kalra S, Sharma M, Adenosine monophosphate-activated protein kinase-based classification of diabetes pharmacotherapy, J Postgrad Med, 2017;63:114–21.
  8. Kalra S, Gupta Y, Choosing injectable therapy: The metabolic fulcrum, JPMA, 2016;66:908.
  9. What is the meaning of the Greek word (város)? Available at: (accessed April 6, 2017).
  10. Varo. Available at: (accessed April 6, 2017).
  11. Varo. Available at: (accessed April 6, 2017).
  12. Kalra S, Gupta Y, Good clinical sense in diabetology, JPMA, 2015;65:904–6.

Further Resources

Share this Article
Related Content In Diabetes
  • Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72